TELO Telomir Pharmaceuticals, Inc.
Fundamentals / CIK 0001971532 / USDTelomir Pharmaceuticals, Inc. reported $4.64M in total assets and a net loss of $5.48M through December 31, 2025 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open TELO in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025-- Dec 31, 2025
-
Operating Income FY 2025-- Operating profit
-
Net Income FY 2025-$5.48M GAAP bottom line
-
Diluted EPS FY 2025-$0.08 Split-adjusted
-
Free Cash Flow FY 2025-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$4.52M Total debt: --
Annual revenue and net income
4 fiscal years (2022 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Research & Development | $2.44M | $2.24M | $1.57M | $833K |
| Total Operating Expenses | $10.54M | $12.24M | $3.94M | $854K |
| Interest Income | $126K | $48K | -- | -- |
| Interest Expense | -- | $4.34M | $1.64M | -- |
| Net Income | -$10.41M | -$16.53M | -$13.07M | -$854K |
| Basic EPS | -$0.33 | -$0.56 | $0.48 | -$0.03 |
| Diluted EPS | -$0.33 | -$0.56 | $0.48 | -$0.03 |
| Basic Shares Outstanding | 31.7M | 29.5M | 27.3M | 26.8M |
| Diluted Shares Outstanding | 31.7M | 29.5M | 27.3M | 26.8M |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Research & Development | $252K | $445K | $468K | $1.30M | $760K | $43K | $337K | $269K |
| Total Operating Expenses | $745K | $1.76M | $1.04M | $2.13M | $1.15M | $5.07M | $2.19M | $2.91M |
| Operating Income | -- | -- | -- | -- | -- | -- | $2.19M | -- |
| Interest Income | $42K | $46K | $52K | $72K | $44K | $1.4K | $8.0K | -- |
| Interest Expense | $1.9K | $3.0K | $1.3K | -- | $0 | $1.3K | $46 | -- |
| Net Income | -$705K | -$1.72M | -$991K | -$2.06M | -$1.10M | -$5.07M | -$2.18M | -$2.90M |
| Basic EPS | -$0.01 | -$0.79 | -$0.03 | -- | -$0.03 | -$0.17 | -$0.07 | -- |
| Diluted EPS | -$0.01 | -$0.79 | -$0.03 | -- | -$0.03 | -$0.17 | -$0.07 | -- |
| Basic Shares Outstanding | 68.8M | 60.8M | 34.4M | -- | 32.4M | 30.0M | 29.8M | -- |
| Diluted Shares Outstanding | 68.8M | 60.8M | 34.4M | -- | 32.4M | 30.0M | 29.8M | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $7.29M | $1.27M | $1.2K | $1.4K |
| Cash & Short-Term Investments | $7.29M | $1.27M | $1.2K | $1.4K |
| Total Current Assets | $7.34M | $1.32M | $435K | $49K |
| Total Non-Current Assets | $0 | $0 | $4.34M | $0 |
| Total Assets | $7.34M | $1.32M | $4.77M | $49K |
| Accounts Payable | -- | -- | $475K | -- |
| Other Current Liabilities | $318K | $93K | $527K | -- |
| Total Current Liabilities | $1.43M | $681K | $1.34M | $986K |
| Total Non-Current Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.43M | $681K | $1.34M | $986K |
| Retained Earnings | -$41.01M | -$30.60M | -$14.06M | -$992K |
| Total Stockholders' Equity | $5.91M | $643K | $3.44M | -$937K |
| Total Equity | $5.91M | $643K | $3.44M | -$937K |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $4.52M | $5.17M | $5.56M | $7.29M | $7.33M | $754K | $403K | $1.27M |
| Cash & Short-Term Investments | $4.52M | $5.17M | $5.56M | $7.29M | $7.33M | $754K | $403K | $1.27M |
| Total Current Assets | $4.64M | $5.37M | $5.79M | $7.34M | $7.40M | $830K | $491K | $1.32M |
| Total Non-Current Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $4.64M | $5.37M | $5.79M | $7.34M | $7.40M | $830K | $491K | $1.32M |
| Other Current Liabilities | -- | -- | $345K | $318K | $93K | $93K | $93K | $93K |
| Total Current Liabilities | $237K | $332K | $827K | $1.43M | $423K | $348K | $652K | $681K |
| Total Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $237K | $332K | $827K | $1.43M | $423K | $348K | $652K | $681K |
| Retained Earnings | -$44.43M | -$43.72M | -$42.00M | -$41.01M | -$38.95M | -$37.85M | -$32.78M | -$30.60M |
| Total Stockholders' Equity | $4.40M | $5.03M | $4.96M | $5.91M | $6.98M | $481K | -$161K | $643K |
| Total Equity | $4.40M | $5.03M | $4.96M | $5.91M | $6.98M | $481K | -$161K | $643K |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Net Income | -$10.41M | -$16.53M | -$13.07M | -$854K |
| Stock-Based Compensation | $5.29M | $6.87M | -- | -- |
| Operating Cash Flow | -$3.69M | -$5.07M | -$3.86M | -$469K |
| Common Stock Issued | $9.60M | $6.83M | $1.00M | -- |
| Financing Cash Flow | $9.71M | $6.34M | $3.86M | $470K |
| Net Change in Cash | $6.02M | $1.26M | -$188 | $1.4K |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$705K | -$1.72M | -$991K | -$2.06M | -$1.10M | -$5.07M | -$2.18M | -$2.90M |
| Stock-Based Compensation | $65K | $199K | $40K | -$7.9K | -$742K | $4.66M | $1.38M | -- |
| Operating Cash Flow | -$586K | -$1.01M | -$1.77M | -$1.20M | -$927K | -$696K | -$863K | -$606K |
| Common Stock Issued | -- | -- | -- | -- | -- | -- | -- | $1.00M |
| Financing Cash Flow | -$68K | $622K | $47K | -- | -- | -- | -- | $1.04M |
| Net Change in Cash | -$655K | -$390K | -$1.73M | -$43K | $6.57M | $351K | -$863K | $431K |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Return on Equity (ROE) | -176.1% | -2571.0% | -380.2% | -- |
| Return on Assets (ROA) | -141.8% | -1248.7% | -273.8% | -1752.8% |
| Current Ratio | 5.14x | 1.94x | 0.33x | 0.05x |
| Quick Ratio | 5.10x | 1.86x | 0.00x | 0.00x |
| EPS Growth (YoY) | -- | -216.7% | -- | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -124.4% | -116.7% | -185.9% | -176.1% | -161.2% | -3353.7% | -- | -2571.0% |
| Return on Assets (ROA) | -118.0% | -109.5% | -159.3% | -141.8% | -152.0% | -1945.3% | -2536.3% | -1248.7% |
| Current Ratio | 19.60x | 16.14x | 7.00x | 5.14x | 17.51x | 2.38x | 0.75x | 1.94x |
| Quick Ratio | 19.07x | 15.55x | 6.72x | 5.10x | 17.33x | 2.17x | 0.62x | 1.86x |
| Operating Income Growth (YoY) | -- | -- | -- | -- | -- | -- | +14.2% | -- |
| EPS Growth (YoY) | -- | -- | -- | -- | -- | -440.0% | -- | -- |